Similar articles

• [An elderly man with known heart failure admitted with cardiogenic shock].

  Hovland A, Fagerheim AK, Hardersen R, Nielsen EW. Hovland A, et al. Tidsskr Nor Laegeforen. 2010 Jul 1;130(13):1352-4. doi: 10.4045/tidsskr.09.0384. Tidsskr Nor Laegeforen. 2010. PMID: 20596117 Norwegian.
• Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.

  [No authors listed] [No authors listed] Prescrire Int. 2005 Oct;14(79):180-6. Prescrire Int. 2005. PMID: 16285075
• Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.

  Weir MR, Rolfe M. Weir MR, et al. Clin J Am Soc Nephrol. 2010 Mar;5(3):531-48. doi: 10.2215/CJN.07821109. Epub 2010 Feb 11. Clin J Am Soc Nephrol. 2010. PMID: 20150448 Review.
• Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.

  Jneid H, Moukarbel GV, Dawson B, Hajjar RJ, Francis GS. Jneid H, et al. Am J Med. 2007 Dec;120(12):1090.e1-8. doi: 10.1016/j.amjmed.2007.02.029. Am J Med. 2007. PMID: 18060931 Review.
• Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?

  McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ. McMurray JJ, et al. Circulation. 2004 Nov 16;110(20):3281-8. doi: 10.1161/01.CIR.0000147274.83071.68. Circulation. 2004. PMID: 15545527 Review. No abstract available.